|
Brain met, surgery, SRS now Docetaxel & Phesgo
|
|
3
|
184
|
22 July 2025
|
|
Lump in axilla
|
|
3
|
154
|
21 July 2025
|
|
Capecitabine tablets and swallowing
|
|
2
|
98
|
18 July 2025
|
|
New bone mets-what next
|
|
5
|
476
|
17 July 2025
|
|
Holistic healing
|
|
42
|
1976
|
14 July 2025
|
|
Have you received capivasertib with fulvestrant?
|
|
0
|
53
|
14 July 2025
|
|
Nuclear bone scan results
|
|
4
|
2395
|
5 July 2025
|
|
We’re looking for people to help shape our response to the Scottish Medicines Consortium’s (SMC) appraisal of elacestrant (korserdu) for treating ER positive, HER-2 negative secondary breast cancer with an ESR1 mutation
|
|
0
|
65
|
2 July 2025
|
|
Xeloda capecitabine weight gain
|
|
10
|
1635
|
15 June 2025
|
|
Lobular Breast Cancer
|
|
12
|
4185
|
27 June 2025
|
|
Constant vomiting
|
|
20
|
639
|
18 June 2025
|
|
Liver misbehaving
|
|
2
|
349
|
15 June 2025
|
|
Elevated CA153 along with new elevated CA125
|
|
9
|
335
|
30 May 2025
|
|
Treatment advice
|
|
1
|
204
|
25 May 2025
|
|
We're looking for people to help shape our response to the Scottish Medicines Consortium's appraisal of capivasertib in combination with fulvestrant for treating hormone receptor positive, HER-2 negative secondary breast cancer after endocrine therapy
|
|
0
|
68
|
22 May 2025
|
|
We’re looking for people to shape our response to NICE’s appraisal for inavolisib (Itovebi) with palbociclib & fulvestrant for treating recurrent HR-positive, HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment
|
|
0
|
100
|
15 May 2025
|
|
Cbd oil and cancer
|
|
12
|
30294
|
5 May 2025
|
|
Help us fix the drugs system - share your experience
|
|
1
|
182
|
29 April 2025
|
|
Three monthly denosumab injections
|
|
6
|
308
|
18 April 2025
|
|
Immunotherapy alone
|
|
2
|
290
|
10 April 2025
|
|
Elacestrant (Orserdu)
|
|
11
|
866
|
7 April 2025
|
|
Help! Ca 15.3 increse but ct scan clear!
|
|
4
|
700
|
6 April 2025
|
|
Freaked out about ca 15.3 levels
|
|
9
|
2687
|
2 April 2025
|
|
We’re looking for people to help shape our submission to NICE’s appraisal for trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer
|
|
1
|
231
|
31 March 2025
|
|
Face skin issues on ribociclib
|
|
2
|
251
|
25 March 2025
|
|
Have you recieved elacestrant (orserdu)?
|
|
1
|
728
|
23 March 2025
|
|
Total hip replacement
|
|
8
|
3975
|
11 March 2025
|
|
HER 2 Positive and HER2 negative
|
|
5
|
1148
|
7 March 2025
|
|
Cording back again
|
|
1
|
238
|
4 March 2025
|
|
Tooth extraction
|
|
9
|
1081
|
27 February 2025
|